ORCL three-lens brief
Evidence-based stock research on ORCL. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both. · Trading at 3% of its 52-week range — deep in the lower band.
- Trading at 3% of its 52-week range — deep in the lower band.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- Underperforming SPY by 26.2pp over 30 days.
- Analyst mean target $251.85 — 78% above current (40 analysts).
- Negative free cash flow last quarterly (-$24.54B).
ORCL closed at $141.70 (-1.41%) as of 2026-07-10. Market cap: $408.16B. P/E (trailing) 24.3. Price is below the 50-day MA and below the 200-day MA. Positives: analyst mean target $251.85 — 78% above current (40 analysts).. Concerns: trading at 3% of its 52-week range — deep in the lower band.; 50-day MA below 200-day MA (death-cross regime); price below both.. Last quarter: Revenue $19.18B, net income $4.22B, free cash flow -$24.54B.
Why three lenses on ORCL, not one.
A single reasoning model has blind spots it doesn’t know about. We examine ORCLacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/ORCL" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath ORCL brief"></iframe>